Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab vs Methotrexate in Early Rheumatoid Arthritis (PREMIER)
NCT00195663Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2000
- Primary completion
- Apr 2004
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in rheumatoid arthritis (RA) (3 arms), sponsored by AbbVie Inc. Primary endpoints: American College of Rheumatology 50% Response at 52 weeks and Modified Total Sharp Score at 52 weeks. Started Dec 2000; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00195663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00195663.